



(51) International Patent Classification:

C12N 15/62 (2006.01) *A61K 48/00* (2006.01)
A61K 39/39 (2006.01) *A61K 39/385* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/041675

(22) International Filing Date:

14 July 2021 (14.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/051,472 14 July 2020 (14.07.2020) US
 63/110,929 06 November 2020 (06.11.2020) US
 63/120,677 02 December 2020 (02.12.2020) US

(71) Applicant: **CUE BIOPHARMA, INC.** [US/US]; 21 Erie Street, Cambridge, Massachusetts 02139 (US).


(72) Inventors: **SEIDEL III, Ronald D.**; c/o Cue Biopharma, Inc., 21 Erie Street, Cambridge, Massachusetts 02139 (US). **CHAPARRO, Rodolfo J.**; 244 Pearl St., Cambridge, Massachusetts 02139 (US). **ROSS, John F.**; c/o Cue Biopharma, Inc., 21 Erie Street, Cambridge, Massachusetts 02139 (US). **LOW, Chee Meng**; c/o Cue Biopharma, Inc., 21 Erie Street, Cambridge, Massachusetts 02139 (US). **SURI, Anish**; c/o Cue Biopharma, Inc., 21 Erie Street, Cambridge, Massachusetts 02139 (US). **MONIZ, Raymond J.**; c/o Cue Biopharma, Inc., 21 Erie Street, Cambridge, Massachusetts 02139 (US). **SAGGU, Gurpanna**; 45 Winter Street, Westwood, Massachusetts 02090 (US).

(74) Agent: **RICIGLIANO, Joseph W.**; Hoffmann & Baron LLP, 6900 Jericho Turnpike, Syosset, New York 11791 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF

FIG. 1



(57) Abstract: The present disclosure provides T cell modulatory polypeptides (T-Cell-MPs) comprising a chemical conjugation site and at least one immunomodulatory polypeptide sequence that may be selected to exhibit reduced binding affinity to its cognate co-immunomodulatory polypeptide. The unconjugated T-Cell-MPs may be conjugated to a molecule displaying an epitope to form a T-Cell-MP-epitope conjugate. The T-Cell-epitope conjugates are useful for modulating the activity (e.g., increasing proliferation or cytotoxic activity) of T cells specific to the conjugate epitope, and accordingly for use as therapeutics.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

03 March 2022 (03.03.2022)